Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

Murray Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Bohm; Felix Mahfoud; Horst Sievert; Nina Wunderlich; Lars C Rump; Oliver Vonend; Michael Uder; Mel D Lobo; Mark J Caulfield; Andrejs Erglis; Michel Azizi; Marc Sapoval; Suku Thambar; Alexandre Persu; Jean P M Renkin; Heribert Schunkert; Joachim Weil; Uta C Hoppe; Antony Walton; Dierk Scheinert; Thomas Binder; Andrzej Januszewicz; Adam Witkowski; Luis Miguel Ruilope; Robert Whitbourn; Heike Bruck; Mark O Downes; Thomas F Luscher; Alan G M Jardine; Mark W Webster; Thomas Zeller; Jerzy Sadowski; Krzysztof Bartus; Craig A Straley; Neil Barman; David P Lee; Ronald M Witteles; Vivek Bhalla; Joseph M Massaro

doi:10.1016/S0140-6736(10)62039-9

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

Murray Esler, Henry Krum, Paul A Sobotka, Markus P Schlaich, Roland E Schmieder, Michael Bohm, Felix Mahfoud, Horst Sievert, Nina Wunderlich, Lars C Rump, Oliver Vonend, Michael Uder, Mel D Lobo, Mark J Caulfield, Andrejs Erglis, Michel Azizi, Marc Sapoval, Suku Thambar, Alexandre Persu, Jean P M RenkinHeribert Schunkert, Joachim Weil, Uta C Hoppe, Antony Walton, Dierk Scheinert, Thomas Binder, Andrzej Januszewicz, Adam Witkowski, Luis Miguel Ruilope, Robert Whitbourn, Heike Bruck, Mark O Downes, Thomas F Luscher, Alan G M Jardine, Mark W Webster, Thomas Zeller, Jerzy Sadowski, Krzysztof Bartus, Craig A Straley, Neil Barman, David P Lee, Ronald M Witteles, Vivek Bhalla, Joseph M Massaro

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

2051 Citations (Scopus)

Abstract

In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (?150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months

Original language	English
Pages (from-to)	1903 - 1909
Number of pages	7
Journal	The Lancet
Volume	376
Issue number	9756
DOIs	https://doi.org/10.1016/S0140-6736(10)62039-9
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(10)62039-9

Cite this

Esler, M., Krum, H., Sobotka, P. A., Schlaich, M. P., Schmieder, R. E., Bohm, M., Mahfoud, F., Sievert, H., Wunderlich, N., Rump, L. C., Vonend, O., Uder, M., Lobo, M. D., Caulfield, M. J., Erglis, A., Azizi, M., Sapoval, M., Thambar, S., Persu, A., ... Massaro, J. M. (2010). Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet, 376(9756), 1903 - 1909. https://doi.org/10.1016/S0140-6736(10)62039-9

@article{34b7f8439a254cf5a1cf946943fefd85,

title = "Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial",

abstract = "In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (?150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months",

author = "Murray Esler and Henry Krum and Sobotka, \{Paul A\} and Schlaich, \{Markus P\} and Schmieder, \{Roland E\} and Michael Bohm and Felix Mahfoud and Horst Sievert and Nina Wunderlich and Rump, \{Lars C\} and Oliver Vonend and Michael Uder and Lobo, \{Mel D\} and Caulfield, \{Mark J\} and Andrejs Erglis and Michel Azizi and Marc Sapoval and Suku Thambar and Alexandre Persu and Renkin, \{Jean P M\} and Heribert Schunkert and Joachim Weil and Hoppe, \{Uta C\} and Antony Walton and Dierk Scheinert and Thomas Binder and Andrzej Januszewicz and Adam Witkowski and Ruilope, \{Luis Miguel\} and Robert Whitbourn and Heike Bruck and Downes, \{Mark O\} and Luscher, \{Thomas F\} and Jardine, \{Alan G M\} and Webster, \{Mark W\} and Thomas Zeller and Jerzy Sadowski and Krzysztof Bartus and Straley, \{Craig A\} and Neil Barman and Lee, \{David P\} and Witteles, \{Ronald M\} and Vivek Bhalla and Massaro, \{Joseph M\}",

year = "2010",

doi = "10.1016/S0140-6736(10)62039-9",

language = "English",

volume = "376",

pages = "1903 -- 1909",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9756",

}

Esler, M, Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, Bohm, M, Mahfoud, F, Sievert, H, Wunderlich, N, Rump, LC, Vonend, O, Uder, M, Lobo, MD, Caulfield, MJ, Erglis, A, Azizi, M, Sapoval, M, Thambar, S, Persu, A, Renkin, JPM, Schunkert, H, Weil, J, Hoppe, UC, Walton, A, Scheinert, D, Binder, T, Januszewicz, A, Witkowski, A, Ruilope, LM, Whitbourn, R, Bruck, H, Downes, MO, Luscher, TF, Jardine, AGM, Webster, MW, Zeller, T, Sadowski, J, Bartus, K, Straley, CA, Barman, N, Lee, DP, Witteles, RM, Bhalla, V & Massaro, JM 2010, 'Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial', The Lancet, vol. 376, no. 9756, pp. 1903 - 1909. https://doi.org/10.1016/S0140-6736(10)62039-9

TY - JOUR

T1 - Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

AU - Esler, Murray

AU - Krum, Henry

AU - Sobotka, Paul A

AU - Schlaich, Markus P

AU - Schmieder, Roland E

AU - Bohm, Michael

AU - Mahfoud, Felix

AU - Sievert, Horst

AU - Wunderlich, Nina

AU - Rump, Lars C

AU - Vonend, Oliver

AU - Uder, Michael

AU - Lobo, Mel D

AU - Caulfield, Mark J

AU - Erglis, Andrejs

AU - Azizi, Michel

AU - Sapoval, Marc

AU - Thambar, Suku

AU - Persu, Alexandre

AU - Renkin, Jean P M

AU - Schunkert, Heribert

AU - Weil, Joachim

AU - Hoppe, Uta C

AU - Walton, Antony

AU - Scheinert, Dierk

AU - Binder, Thomas

AU - Januszewicz, Andrzej

AU - Witkowski, Adam

AU - Ruilope, Luis Miguel

AU - Whitbourn, Robert

AU - Bruck, Heike

AU - Downes, Mark O

AU - Luscher, Thomas F

AU - Jardine, Alan G M

AU - Webster, Mark W

AU - Zeller, Thomas

AU - Sadowski, Jerzy

AU - Bartus, Krzysztof

AU - Straley, Craig A

AU - Barman, Neil

AU - Lee, David P

AU - Witteles, Ronald M

AU - Bhalla, Vivek

AU - Massaro, Joseph M

PY - 2010

Y1 - 2010

N2 - In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (?150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months

AB - In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (?150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months

UR - http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-51GXJ3C-2&_user=542840&_coverDate=12%2F10%2F2010&_rdoc=1&_fmt=high&_orig=gateway&_orig6

U2 - 10.1016/S0140-6736(10)62039-9

DO - 10.1016/S0140-6736(10)62039-9

M3 - Article

SN - 0140-6736

VL - 376

SP - 1903

EP - 1909

JO - The Lancet

JF - The Lancet

IS - 9756

ER -

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

Abstract

UN SDGs

Access to Document

Other files and links

Cite this